200195-01-3

Basic information

• Product Name: 7-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]-3,4-dihydro-2H-1,4-benzoxazin-3-one
• Synonyms: CI-1030; PD-172760
• CAS NO: 200195-01-3
• Molecular Formula: C₁₉H₂₀ClN₃O₂
• Molecular Weight: 357.84315
• Mol File: 200195-01-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 7-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]-3,4-dihydro-2H-1,4-benzoxazin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]-3,4-dihydro-2H-1,4-benzoxazin-3-one(200195-01-3)
• EPA Substance Registry System: 7-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]-3,4-dihydro-2H-1,4-benzoxazin-3-one(200195-01-3)

Safety Data

• Hazardous Substances Data: 200195-01-3(Hazardous Substances Data)

Upstream product

• 200195-14-8 4-(chloroacetyl-amino)-3-hydroxy-benzaldehyde 
• 253687-16-0 7-(hydroxymethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 200195-19-3 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbaldehyde 
• 704-13-2 5-formyl-2-nitrophenol 
• 38212-33-8 4-(4-chlorophenyl) piperazine 
• 253687-19-3 7-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-4H-benz[1,4]oxazin-3-one 
• 200195-17-1 2-chloro-N-(4-[1,3]dioxan-2-yl-2-hydroxy-phenyl)-acetamide 
• 200195-16-0 2-(3-hydroxy-4-nitro-phenyl)-1,3-dioxane 

Relevant articles and documents

Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors

The present invention relates to a method of treating dementia or cognitive deficits associated with Alzheimer's Disease or Parkinson's Disease in a mammal, including a human, by administering to the mammal a D4 dopamine receptor antagonist in combination with an acetylcholine esterase inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 dopamine receptor antagonist and an acetylcholine esterase inhibitor.

A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: Discovery of a potential atypical antipsychotic agent

As part of a program to develop dopamine D4 antagonists for the treatment of schizophrenia, we discovered a series of 6- and 7- (phenylpiperazinyl)- and -(phenylpiperidinyl)methylbenzoxazinones through mass screening of our compound library. A structure-a